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Chief Medical Officers’ Perceptions of
Disease Management Programs
GANG XU, Ph.D.1, LISA E. PADDOCK, M.P.H.1, JOHN P. O’CONNOR, Ph.D.1,
DAVID B. NASH, M.D., M.B.A.,1 and MARK ZITTER2

ABSTRACT
The purpose of this article is to examine chief medical officers’ (CMOs) perception of disease
management programs. Five open-ended questions, each addressing a major issue in the development of disease management programs, were given to 31 CMOs who attended a series
of invitation-only conferences on disease management in the fall of 1999. Qualitative data
analysis was conducted using the transcripts on each of the issues. Overall, the CMOs viewed
the emergence of capitated disease management programs positively. They considered the
population of a program to be the contractual patients and/or those at risk for the target disease. On the issue of quality and cost, they preferred an optimal balance between the two.
They saw the Internet as an opportunity for the education of patients as well as providers.
However, they were concerned about patient confidentiality and further widening of the gap
between those who have the financial means to access healthcare and those who do not. In
spite of concerns expressed about the current generation of disease management programs,
the CMOs held an optimistic view of the future of these programs. To become better accepted,
disease management programs must address the issues of confidentiality and quality of care.

A

sessment. 3 DM emphasizes preventive care for
all members of a plan. Primarily, DM is integrated into the healthcare system by educating
patients and providers. As DM evolves, the Internet is being used more frequently as a means
of patient and provider education.3 The chief
medical officer (CMO), a role just now being
defined, often acts as the advocate and portal
for DM to managed care organizations, hospitals, and healthcare systems.
Presently, in the United States there are two
main provider organization reimbursement
methods: full-risk sharing (capitation [CP]) and

from
an “industrial model of medicine” to an
“information model” is the emergence of disease management (DM).1 DM is a mechanism
to coordinate medical resources for patients
across the entire healthcare delivery system. 2
The main features of DM include a comprehensive focus on a particular disease,
population-oriented health and medical care,
emphasis on evidence-based medicine and
demonstrated best practices, mechanisms to
connect treatment and information across care
settings, cost containment, and outcome asCCOMPANYING THE HISTORIC AL CHANG E
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fragmental contractual payment (fee for service
[FFS]). CP refers to a specific amount of money
that is received for a set of services.4 FFS, on
the other hand, refers to monies received for
every service provided. The percentage of
health maintenance organizations using CP
and FFS reimbursement for primary care and
specialty care physicians has risen drastically
from 1993 to 1998.5 CP has not grown as
quickly for hospitals and systems because assuming full risk for patients increases the
chance of economic loss.6 Widespread concern
among both payers and providers about the
risks of the CP approach raises doubts about
its long-term feasibility.
Other issues of major concern are quality and
cost of care. Historically, DM programs were
initiated to provide quality care that is cost effective.3,7,8 However, some DM programs have
focused only on reduced costs and have not improved care.9 This raises concern about the real
purpose of DM programs.7
DM obviously poses many challenges for
providers and organizations, and particularly
for decision makers. For instance, how to define a DM population remains problematic. As
more DM programs arise for various disease
states, defining the target population becomes
even more difficult. To be cost effective, a program must be targeted to the appropriate members. Other issues that plague decision makers
involve information technology and patient
privacy.
These are important and urgent questions
facing the current generation of DM programs.
We presented these questions to a group of
CMOs in the United States. Through both formal and interactive sessions, common themes
emerged from their responses to each question.
The purpose of this article is to examine how
CMOs’ perceptions can shed light on the further evolution of DM.

METHODS

the fall of 1999. Forty-one attending CMOs
served as participants in the study. The conferences were held in three locations: San Francisco, Chicago, and Washington, DC. The respective numbers of CMOs in each location
were 15, 18, and 8. The participants represented
a broad array of health systems, hospitals,
physician organizations, and health plans.
Instrument
Questions directly relevant to the development and implementation of DM programs
were initially developed based on informal discussion and literature review. Three physicians
from Thomas Jefferson University Hospital,
CareWise Inc., and Evanston Northwestern
Healthcare reviewed the questions for the importance of the issues. A survey consisted of
five open-ended questions relating to comparisons between reimbursement types, definition
of the program population, role of non-physician leadership, information access, and confidentiality. The questions were presented to the
participants during an interactive discussion
session at each conference location. These five
questions were:
1. What is the impact of full risk sharing (capitation—CP) versus fragmented contractual
payment (fee for service—FFS) on disease
management?
2. What is the best definition of a population
in disease management?
3. How do the non-physician leadership and
the drive for a positive Return on Investment (ROI) affect the development and implementation of disease management programs?
4. What do you see as the impact of the Internet and unfettered access to health information on disease management programs and
the role of the physician?
5. What are some of the concerns regarding patient confidentiality that will affect disease
management programs?

Participants
The study was conducted at the Second National Conference of the Society of Chief Medical Officers (Solution Series Workshop) during

Procedure, data collection, and analysis
Each participant was asked to write their answers to these five questions presented to them

21

DISEASE MANAGEMENT PROGRAMS

during a discussion session. There was no time
limit on the completion of the questions. Each
participant worked independently while answering the questions.
Qualitative analysis10 was performed to
group the data into major categories. The procedure consisted of three steps. In the first step,
two of the authors reviewed the detailed transcripts, and themes were derived from the responses to each question. In the second step,
reviewers analyzed the themes, and a general
theme from each question was extracted. This
theme is then illustrated in detail, using direct
quotations. In the third step, story-like summary responses for each question were developed. The final results were based on these
themes and summarized in a descriptive format.

Although the CMOs agreed that CP might
have a potentially higher risk than FFS, the risk
taken by CP was seen positively:
“The greater the risk, the greater the incentive to have effective disease mangement programs.”
“Full risk increases the success of implementation.”
2. What is the best definition of a population
in DM?
Although the definitions of a population in DM
varied among the CMOs, most tended to define it based on two components: the disease
state and the financially contracted membership. In reference to disease state, the CMOs
described the DM population as:

RESULTS
The themes derived for each question were
compared across the three locations. Because
similar themes were derived at each location,
the results are reported combining the data
from the three locations. The findings are presented in the same sequence they were asked.
1. What is the impact of full risk sharing (capitation—CP) versus fragmented contractual
payment (fee for service—FFS) on disease
management?
An overwhelming majority of the CMOs felt
that CP is superior to FFS in terms of DM. CP
is a “a much greater driver for implementation
of disease management programs” and it
“aligns the incentives in a way that would facilitate development of DM.”
Specifically, the advantages cited by the
CMOs favoring CP consist of management, incentives, and ownership, as noted below:
“FFS may cause unintended conflicts.”
“CP is more likely to induce physician cooperation through alignment of financial incentives.”
“FFS seems doomed to fail [because] the
physicians have no ownership.”

“A distinct group who have a defined and
recognized cluster of symptoms or a disease.”
“Those with the disease and those who
have potential to develop the disease.”
“The population of present and future persons at risk of illness.”
In reference to the financially contracted
membership, the CMOs described the DM population as:
“The entire enrolled membership.”
“. . . the risk population financially contracted . . .”
“Contractual population with a disease
state, diagnosed or at risk for disease
state.”
3. How do the non-physician leadership and the
drive for a positive Return on Investment
(ROI) affect the development and implementation of disease management programs?
The reactions to the non-physicians’ leadership
role in DM were mixed. However, most CMOs
commented that non-physician leadership was
seen hand in hand with a focus on positive ROI.
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To support the need for non-physician leadership, some CMOs agreed that a positive ROI
“drives everything” and is “the bottom line.”
Similar viewpoints were expressed, such as:
“No margin, no mission . . .”
“It will eliminate ineffective programs . . .”
On the other hand, a majority of the CMOs
said that DM programs run by non-physician
leaders would become like business enterprises where the bottom line was the key driving force. Therefore, CMOs feared that the
optimal balance between cost and quality in
such DM programs would not be achievable.
According to some CMOs, “Non-physician
leadership focuses on short-term returns
whereas DM return is long-term.” The CMOs
also perceived that there might be a bias toward selecting certain types of diseases for
management if cost becomes the highest priority. If achieving a positive ROI becomes the
sole criterion for implementation of a DM program, there could be unfortunate consequences. Thus, some CMOs responded rather
negatively:
“Non-physician decision makers and the
demand for an ROI may inhibit the development and implementation of the
program.”
“There would be a bias for selecting diseases . . . as opposed to a pure medical/public health model of what the
population needs.”
4. What do you see as the impact of the Internet and unfettered access to health information on disease management programs and
the role of the physician?
Almost all of the CMOs perceived that the influence of the Internet on healthcare is inevitable and positive. Most remarkable is the
enormous volume of information that can be
accessed by patients. “It is revolutionary,”
summarized one CMO, representing the general feeling of the participants in reaction to the
new reality of patient and consumer empowerment. The Internet has become a “driving

force” in this information age. Other respondents replied:
“The Internet will increase patients’ power
with full information.”
“Patients will become more assertive, educated and key decision-makers.”
Thus, the CMOs remarked about a gradual
change in the physicians’ role. Physicians are
facing patients armed with large amounts of information about disease, healthcare, and other
issues for which physicians may not be prepared. Consequently, the physicians’ role in
this new environment should be making sure
that the patient is obtaining quality information:
“Physicians will play a large role in providing accurate evidence based information on the Internet.”
“Physicians have to help patients sift
through the information, and assume
more responsibility for the management
of their disease.”
“Physicians will become knowledge brokers rather than just service providers.
If not, they will be pushed to the periphery.”
In the view of these CMOs, the information age
has also widened the gap between those who
have the financial means to access healthcare
and those who do not. Only a small percentage
of American households have Internet access,
which is directly related to income and is unevenly distributed across racial and ethnic
groups.11,12 This greatly biases the distribution
of healthcare information. The CMOs expressed great concern over this issue.
“The sickest members of our society are
probably on the whole ‘later adapters.’ ”
“Medicaid population is not likely to use
the Internet.”
5. What are some of the concerns regarding patient confidentiality that will affect disease
management programs?

DISEASE MANAGEMENT PROGRAMS

Great concern was expressed over the confidentialty of patients’ information through the
process of DM. Universally, the CMOs replied
that “there is no confidentiality” in DM programs, at least not as defined by the traditional
standard of the one-on-one doctor–patient relationship. To integrate the different aspects of
care in DM, patients’ information that was previously shared only with their own doctors will
now be shared with others. The questions
raised among our respondents were, “Who
owns the data?”, “Will there be legislative oversight?”, “Who can access it?”, “under what circumstances?”, and “for what purpose?”
In spite of these concerns, most CMOs suggested that patient confidentiality is not an issue of DM per se; rather, it is an issue of implementation:
“Patients and physicians will buy into the
program if somehow names could be
blinded.”
“This will depend on implementation.
Systems that permit option and presence [promoting the] physician and patient relationship will succeed in complying with confidentiality required.

SUMMARY AND CONCLUSION
This survey, though limited in scope, represents a good cross-section of the nation’s decision makers from health systems, hospitals,
and health plans. Similarities among the participants in three locations support the generality of the findings. Answers to several DMrelated questions confirmed literature findings
that there will be greater utilization and influence of DM in healthcare organizations within
the next 3 years.6 Specifically, CMOs felt that
capitated reimbursement will create the most
successful DM programs because risk will be
shared. In general, CMOs supported a well-defined DM population, balancing cost and quality, integration of technology, and increased action to protect patient confidentiality.
Perhaps the most difficult and challenging
task facing healthcare providers is finding an
optimal balance between short-term DM pro-
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gram expenditures and outcome improvement
and long-term cost reductions generated.8 The
CMOs understand that positive ROI is essential for the DM programs of the future. Many
DM programs, especially those run by managed care organizations, are forced to focus on
diseases and interventions that yield a rapid
ROI. Outcome improvement may become a
secondary issue. This could cause the basic objectives of DM (i.e., disease prevention and
health promotion) to be neglected.13,14 The
CMOs feel strongly about creating a balance
between cost and outcome improvements.
They do not want to have a “failed” program
because of low quality.
Many segments in healthcare already benefit from the advance of technology. Perhaps the
most noticeable gain is by the patients who,
with an unprecedented access to information,
demand services they have read about on the
Internet. The CMOs, although welcoming the
information age, indicated that providers need
to prepare for changes in the dissemination of
healthcare information. A system that was once
“provider-oriented” healthcare is quickly becoming “consumer-focused.”
Almost inevitably, the advancement of technology raises many issues. Among them is the
security of confidential healthcare information.
This issue becomes more apparent within an
integrated effort, such as a DM progrom, where
sharing of information facilitates data collection, disease prevention, and health promotion.
All of these aspects are deemed crucial for a
DM program to succeed. To this extent, our respondents agreed and noted that privacy issues
can be overcome without jeopardizing the fundamentals of the program.
The CMOs also expressed concerns about social responsibility. They envisioned a wider
and further disparity that may occur between
the economic stratum because of the advancement of technology and resulting access of information. This implies that healthcare
providers have some obligations to narrow
these gaps and help those who may not have
the resources needed to access information.
The study results indicate that CMOs hold a
positive view of current developments in DM.
They welcome capitated reimbursement and
the impact of the information age. The confi-
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dence expressed by this national sample of decision makers suggests that despite the presence of recognized barriers, DM has a secure
role in the future.
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